Boston-based Novophage has raised $5.7 million in a Series A financing round led by Flybridge Capital Partners. Founder Collective, Boston University, and strategic investors Chevron Technology Ventures and The Kraft Group also participated in the round. The news was first reported by Scott Kirsner of the Boston Globe. Novophage engineers viruses (phages) to combat bacterial contamination in industries like oil and gas, paper, and heating and cooling systems. As part of the financing, Micah Rosenbloom (co-founder of Brontes Technologies) has joined the firm as CEO. Xconomy profiled Novophage back in March 2009, when the company was more focused on therapeutic applications.
Author: Gregory T. Huang
Greg is a veteran journalist who has covered a wide range of science, technology, and business. As former editor in chief, he overaw daily news, features, and events across Xconomy's national network. Before joining Xconomy, he was a features editor at New Scientist magazine, where he edited and wrote articles on physics, technology, and neuroscience. Previously he was senior writer at Technology Review, where he reported on emerging technologies, R&D, and advances in computing, robotics, and applied physics. His writing has also appeared in Wired, Nature, and The Atlantic Monthly’s website. He was named a New York Times professional fellow in 2003.
Greg is the co-author of Guanxi (Simon & Schuster, 2006), about Microsoft in China and the global competition for talent and technology. Before becoming a journalist, he did research at MIT’s Artificial Intelligence Lab. He has published 20 papers in scientific journals and conferences and spoken on innovation at Adobe, Amazon, eBay, Google, HP, Microsoft, Yahoo, and other organizations. He has a Master’s and Ph.D. in electrical engineering and computer science from MIT, and a B.S. in electrical engineering from the University of Illinois, Urbana-Champaign.
View all posts by Gregory T. Huang